Argenta announces integrated drug discovery collaboration with Boehringer Ingelheim
Posted: 17 April 2013 | | No comments yet
Argenta has signed a collaboration agreement with Boehringer Ingelheim…
Argenta, a Galapagos NV (Euronext: GLPG) company that provides drug discovery services from target validation to development candidate nomination, announced today that it has signed a collaboration agreement with Boehringer Ingelheim. Under the terms of the agreement, Argenta will apply its extensive respiratory drug discovery services to an undisclosed target within Boehringer Ingelheim’s respiratory disease portfolio.
Commenting on the agreement, Dr. John Montana, Argenta’s Managing Director said, “We are delighted to have secured this contract with Boehringer Ingelheim, one of the world’s leading companies in the development of drugs for respiratory diseases, and it is testament to the strength and depth of Argenta’s integrated drug discovery capabilities and expertise in this therapeutic area. We look forward to a fruitful collaboration leading to the delivery of pre-clinical candidates against the target of interest.”